DANAHER CORP /DE/ News
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
see moreDANAHER CORP /DE/ Market News
5h
Danaher $9.9B Masimo Deal: EPS Upside, Risks Ahead
- Danaher’s announced acquisition of Masimo for roughly $9.9 billion reshapes DHR’s diagnostics and monitoring exposure. The deal—cash at $180 per share—targets patient-monitoring technology and offers near-term EPS accretion and multi-year synergy potential, while integration execution and regulatory review pose the main risks.
7d
Danaher’s $10B Masimo Buy: $180 Deal Shakes DHR Up
Danaher announced a roughly $10 billion all-cash purchase of Masimo at $180 per share, a deal billed as near-term EPS accretive with meaningful cost and revenue synergies. The acquisition bolsters Danaher’s diagnostics and patient-monitoring capabilities; markets reacted with a sharp rise in Masimo shares and modest pressure on DHR as investors weigh integration and financing.
14d
Danaher Tops Q4; Diagnostics & Precision Push Now!
Danaher reported stronger-than-expected Q4 results, raised 2026 guidance range, and showed tangible momentum in diagnostics—driven by new-product launches, a stabilization in China, and a strategic tie-up with AstraZeneca—positioning DHR for durable growth across life-science instruments and molecular diagnostics.
21d
Danaher Q4: Biotech Lifts Growth, Margins Slip Now
Danaher reported Q4 strength in biotechnology but saw operating margins compress across segments. Revenue beat and EPS exceeded expectations, yet investors focused on margin pressure and cautious 2026 guidance—driving early-February share volatility.